Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Delmar

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Diabetes|July 25, 2007
The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytesAnne Mazzucotelli, Nathalie Viguerie, Claire Tiraby, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 31, 2025
Biomarker treatment effects in two phase 3 trials of gantenerumabTobias Bittner, Matteo Tonietto, Gregory Klein, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2024
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)Anuja Neve, Bibha Das, Jakub Wojtowicz, et al.
Alzheimer'S Research & Therapy|December 10, 2017
A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Ophthalmology. Retina|May 4, 2019
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular DegenerationUsha Chakravarthy, Clare Bailey, David Brown, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentLuka Kulic, Fabien Alcaraz, Gregory Klein, et al.
Journal of Alzheimer'S Disease : JAD|December 17, 2024
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)Mercè Boada, Anuja Neve, Bibha Das, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJanice Smith, Catherine J Mummery, Jeffrey L Cummings, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Diabetes|July 25, 2007
The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytesAnne Mazzucotelli, Nathalie Viguerie, Claire Tiraby, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 31, 2025
Biomarker treatment effects in two phase 3 trials of gantenerumabTobias Bittner, Matteo Tonietto, Gregory Klein, et al.
Journal of Alzheimer'S Disease : JAD|August 23, 2024
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)Anuja Neve, Bibha Das, Jakub Wojtowicz, et al.
Alzheimer'S Research & Therapy|December 10, 2017
A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Ophthalmology. Retina|May 4, 2019
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular DegenerationUsha Chakravarthy, Clare Bailey, David Brown, et al.
Alzheimer'S Research & Therapy|September 29, 2018
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's diseaseSusanne Ostrowitzki, Robert A Lasser, Ernest Dorflinger, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentLuka Kulic, Fabien Alcaraz, Gregory Klein, et al.
Journal of Alzheimer'S Disease : JAD|December 17, 2024
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD)Mercè Boada, Anuja Neve, Bibha Das, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJanice Smith, Catherine J Mummery, Jeffrey L Cummings, et al.
Pageof 5